Zhejiang Asia-Pacific Pharmaceutical Co., Ltd. 2025 Annual Internal Control Self-Evaluation Report
Pursuant to the "Basic Norms for Enterprise Internal Control" and its supporting guidelines, as well as other internal control regulatory requirements, and in conjunction with Zhejiang Asia-Pacific Pharmaceutical Co., Ltd.'s (hereinafter referred to as the "Company") internal control system and evaluation methods, based on daily and special supervision of internal controls, we have evaluated the effectiveness of the Company's internal controls as of December 31, 2025 (the benchmark date for the internal control evaluation report).
I. Important Statement
In accordance with the requirements of the internal control normative system for enterprises, establishing, improving, and effectively implementing internal controls, evaluating their effectiveness, and truthfully disclosing the internal control evaluation report are the responsibilities of the Company's Board of Directors. The Audit Committee supervises the establishment and implementation of internal controls by the Board of Directors; management is responsible for organizing and leading the daily operation of the Company's internal controls.
The Company's Board of Directors and its directors and senior management guarantee that this report contains no false records, misleading statements, or material omissions, and they shall bear individual and joint legal liability for the truthfulness, accuracy, and completeness of the report's content.